<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5897">
  <stage>Registered</stage>
  <submitdate>29/07/2015</submitdate>
  <approvaldate>29/07/2015</approvaldate>
  <nctid>NCT02513394</nctid>
  <trial_identification>
    <studytitle>PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer</studytitle>
    <scientifictitle>PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym>PALLAS</trialacronym>
    <secondaryid>ABCSG 42</secondaryid>
    <secondaryid>AFT-05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Palbociclib
Treatment: drugs - Standard Adjuvant Endocrine Therapy

Experimental: Arm A - Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.

Other: Arm B - Standard adjuvant endocrine therapy for a duration of at least 5 years.


Treatment: drugs: Palbociclib


Treatment: drugs: Standard Adjuvant Endocrine Therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Invasive Disease Free Survival (iDFS) - To compare invasive disease-free survival (iDFS) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer (EBC).</outcome>
      <timepoint>The expected study duration to primary analysis of iDFS is 4.8 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the safety of 2 years of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone. (distant recurrence-free survival (DRFS), locoregional recurrences-free survival (LRRFS), and overall survival (OS) - To compare the following endpoints: iDFS excluding second primary cancers of non-breast origin, distant recurrence-free survival (DRFS), locoregional recurrences-free survival (LRRFS), and overall survival (OS).</outcome>
      <timepoint>The expected study duration to primary analysis of iDFS is 4.8 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed informed consent prior to study specific procedures.

          -  Age =18 years (or per national guidelines).

          -  Pre- and postmenopausal women or men with Stage II (Stage IIA limited to max. 1000
             patients) or Stage III early invasive breast cancer

          -  Patients with multicentric and/or multifocal and/or bilateral early invasive breast
             cancer are eligible if all histopathologically examined tumors meet pathologic
             criteria for ER+ and/or PR+ and HER2-.

          -  Patients must have histologically confirmed ER+ and/or PR+, HER2-, early invasive
             breast cancer.

          -  Patients must have undergone breast surgery for the current malignancy. FFPE tumor
             tissue block must be confirmed to be received at the central sample repository prior
             to randomization.

          -  ECOG performance status 0-1.

          -  Patients must be able and willing to swallow and retain oral medication.

          -  Serum or urine pregnancy test must be negative in premenopausal women within 14 days
             of randomization, or in women with amenorrhea of less than 12 months at time of
             randomization.

          -  Patients who received neo/adjuvant therapy must be after last dose of chemotherapy
             and/or biologic therapy and must have sufficient resolution of side effects.

          -  Patients who received breast/axilla/post-mastectomy chest wall radiotherapy must be
             after last dose of radiotherapy and must have sufficient resolution of side effects.

          -  Patients must have sufficient resolution of any surgical side effects (no active wound
             healing complications).

        -Patients must either be initiating or have already started adjuvant hormonal treatment. -

          -  Patients who already received neo/adjuvant endocrine therapy are eligible as long as
             they are enrolled within 12 months of initial histological diagnosis and after
             completing no more than 6 months of adjuvant endocrine therapy.

          -  Absolute neutrophil count = 1,500/µL

          -  Platelets = 100,000/ mm3

          -  Hemoglobin = 10g/dL

          -  Total serum bilirubin = ULN; or total bilirubin = 3.0 × ULN with direct bilirubin
             within normal range in patients with documented Gilbert's Syndrome.

          -  Aspartate amino transferase (AST or SGOT) and alanine amino transferase (ALT or SGPT)
             = 1.5 × institutional ULN.

          -  Serum creatinine within normal institutional limits or creatinine clearance = 60
             mL/min/1.73 m2 for patients with serum creatinine levels above institutional ULN.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Concurrent therapy with other Investigational Products.

          -  Prior therapy with any CDK inhibitor.

          -  Patients with Stage I or IV breast cancer are not eligible.

          -  History of allergic reactions attributed to compounds of chemical or biologic
             composition similar to palbociclib.

          -  Patients receiving any medications or substances that are potent inhibitors or
             inducers of

          -  CYP3A isoenzymes within 7 days of randomization.

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements.

          -  Pregnant women, or women of childbearing potential without a negative pregnancy test
             within 14 days prior to randomization.

        -Patients with a history of any malignancy are ineligible (for exceptions see: Pallas -

          -  Protocol, v1.0, Exclusion criteria 8).

          -  Patients who previously received endocrine therapy within 5 years prior to diagnosis
             of the current malignancy.

          -  Patients on combination antiretroviral therapy.

          -  Patients with clinically significant history of any liver disease.

          -  Patients receiving concurrent exogenous hormone therapy (topical vaginal estrogen
             therapy is allowable).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>4600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2025</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Southern Highlands Cancer Centre - Bowral</hospital>
    <hospital>Coffs Harbour Health Campus - MNCCI - Coffs Harbour</hospital>
    <hospital>The Breast &amp; Endocrine Centre - Gateshead</hospital>
    <hospital>CCLHD/Gosford &amp; Wyong Hospitals - Gosford</hospital>
    <hospital>Orange Health Service - Orange</hospital>
    <hospital>Macquarie University Hospital - Sydney</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>Cancer Care Services, Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>The Northern Hospital - Epping</hospital>
    <hospital>St Vincent's Hospital Cancer Centre - Fitzroy</hospital>
    <hospital>Barwon Health - Geelong</hospital>
    <hospital>Peninsula Health - Frankston Hospital - Melbourne</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Western Health, Sunshine Hospital - St. Albans</hospital>
    <hospital>South West Oncology - Warrnambool</hospital>
    <hospital>St John of God Bunbury Hospital - Bunbury</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch, Perth</hospital>
    <hospital>Breast Cancer Research Centre - Perth</hospital>
    <postcode> - Bowral</postcode>
    <postcode> - Coffs Harbour</postcode>
    <postcode> - Gateshead</postcode>
    <postcode> - Gosford</postcode>
    <postcode> - Orange</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Epping</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - St. Albans</postcode>
    <postcode> - Warrnambool</postcode>
    <postcode> - Bunbury</postcode>
    <postcode> - Murdoch, Perth</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alaska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Central</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo León</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Toluca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Aargau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Graubünden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Tessin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Fribourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Luzern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St.Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua County</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Alliance Foundation Trials, LLC.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Austrian Breast &amp; Colorectal Cancer Study Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>NSABP Foundation Inc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>PrECOG, LLC.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Breast International Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Pfizer</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, two arm, international, multicenter, randomized, open-label Phase III
      study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine
      therapy for patients with HR+ / HER2- early breast cancer (EBC).

      The purpose of the PALLAS study is to determine whether the addition of palbociclib to
      adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2-
      early breast cancer. Assessment of a variety of correlative analysis, including evaluation of
      the effect of palbociclib in genomically defined tumor subgroups, is planned.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02513394</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Monica Bertagnolli, MD</name>
      <address>Alliance Foundation Trials, LLC.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Edward Habermehl</name>
      <address />
      <phone />
      <fax />
      <email>info@alliancefoundationtrials.org</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>